<?xml version="1.0" encoding="UTF-8"?>
<ListRecords>
<metadata xmlns:dc="http://purl.org/dc/elements/1.1/">
  <dc:title>Use of corticosteroids in multiple sclerosis by consultant neurologists in the United Kingdom</dc:title>
  <dc:creator>TREMLETT, H. L</dc:creator>
  <dc:creator>LUSCOMBE, D. K</dc:creator>
  <dc:creator>WILES, C. M</dc:creator>
  <dc:contributor>Association of British Neurologists (Funder/Sponsor)</dc:contributor>
  <dc:contributor>Association of British Neurologists (Leeds 1998-04-15)</dc:contributor>
  <dc:relation>Journal of neurology, neurosurgery and psychiatry -- J. neurol. neurosurg. psychiatry, CODEN JNNPAU, ISSN 0022-3050, Vol. 65 (3) , pp. 362-365</dc:relation>
  <dc:relation>Association of British Neurologists</dc:relation>
  <dc:date>1998</dc:date>
  <dc:type>Text</dc:type>
  <dc:type>Conference Paper</dc:type>
  <dc:language>English</dc:language>
  <dc:publisher>BMJ</dc:publisher>
  <dc:format>print</dc:format>
  <dc:format>13 ref</dc:format>
  <dc:subject xml:lang="fr">Maladie inflammatoire</dc:subject>
  <dc:subject xml:lang="fr">Système nerveux central pathologie</dc:subject>
  <dc:subject xml:lang="fr">Système nerveux pathologie</dc:subject>
  <dc:subject xml:lang="fr">Chimiothérapie</dc:subject>
  <dc:subject xml:lang="fr">Conduite à tenir</dc:subject>
  <dc:subject xml:lang="fr">Corticostéroïde</dc:subject>
  <dc:subject xml:lang="fr">Dose efficace</dc:subject>
  <dc:subject xml:lang="fr">Forme clinique</dc:subject>
  <dc:subject xml:lang="fr">Homme</dc:subject>
  <dc:subject xml:lang="fr">Immunodépresseur</dc:subject>
  <dc:subject xml:lang="fr">Modalité traitement</dc:subject>
  <dc:subject xml:lang="fr">Médecin</dc:subject>
  <dc:subject xml:lang="fr">Neurologie</dc:subject>
  <dc:subject xml:lang="fr">Prescription médicale</dc:subject>
  <dc:subject xml:lang="fr">Recommandation</dc:subject>
  <dc:subject xml:lang="fr">Sclérose en plaque</dc:subject>
  <dc:subject xml:lang="fr">Spécialité médicale</dc:subject>
  <dc:subject xml:lang="fr">Traitement</dc:subject>
  <dc:subject xml:lang="fr">Voie administration</dc:subject>
  <dc:coverage xml:lang="fr">Europe</dc:coverage>
  <dc:coverage xml:lang="fr">Royaume Uni</dc:coverage>
  <dc:subject xml:lang="en">Inflammatory disease</dc:subject>
  <dc:subject xml:lang="en">Central nervous system disease</dc:subject>
  <dc:subject xml:lang="en">Nervous system diseases</dc:subject>
  <dc:subject xml:lang="en">Chemotherapy</dc:subject>
  <dc:subject xml:lang="en">Clinical management</dc:subject>
  <dc:subject xml:lang="en">Corticosteroid</dc:subject>
  <dc:subject xml:lang="en">Effective dose</dc:subject>
  <dc:subject xml:lang="en">Clinical form</dc:subject>
  <dc:subject xml:lang="en">Human</dc:subject>
  <dc:subject xml:lang="en">Immunosuppressive agent</dc:subject>
  <dc:subject xml:lang="en">Application method</dc:subject>
  <dc:subject xml:lang="en">Physician</dc:subject>
  <dc:subject xml:lang="en">Neurology</dc:subject>
  <dc:subject xml:lang="en">Medical prescription</dc:subject>
  <dc:subject xml:lang="en">Recommendation</dc:subject>
  <dc:subject xml:lang="en">Multiple sclerosis</dc:subject>
  <dc:subject xml:lang="en">Medical specialty</dc:subject>
  <dc:subject xml:lang="en">Treatment</dc:subject>
  <dc:subject xml:lang="en">Route of administration</dc:subject>
  <dc:coverage xml:lang="en">Europe</dc:coverage>
  <dc:coverage xml:lang="en">United Kingdom</dc:coverage>
  <dc:subject xml:lang="es">Enfermedad inflamatoria</dc:subject>
  <dc:subject xml:lang="es">Sistema nervosio central patología</dc:subject>
  <dc:subject xml:lang="es">Sistema nervioso patología</dc:subject>
  <dc:subject xml:lang="es">Quimioterapia</dc:subject>
  <dc:subject xml:lang="es">Actitud médica</dc:subject>
  <dc:subject xml:lang="es">Corticoesteroide</dc:subject>
  <dc:subject xml:lang="es">Dosis eficaz</dc:subject>
  <dc:subject xml:lang="es">Forma clínica</dc:subject>
  <dc:subject xml:lang="es">Hombre</dc:subject>
  <dc:subject xml:lang="es">Inmunodepresor</dc:subject>
  <dc:subject xml:lang="es">Modalidad tratamiento</dc:subject>
  <dc:subject xml:lang="es">Médico</dc:subject>
  <dc:subject xml:lang="es">Neurología</dc:subject>
  <dc:subject xml:lang="es">Prescripción médica</dc:subject>
  <dc:subject xml:lang="es">Recomendación</dc:subject>
  <dc:subject xml:lang="es">Esclerosis en placa</dc:subject>
  <dc:subject xml:lang="es">Especialidad medical</dc:subject>
  <dc:subject xml:lang="es">Tratamiento</dc:subject>
  <dc:subject xml:lang="es">Vía administración</dc:subject>
  <dc:coverage xml:lang="es">Europa</dc:coverage>
  <dc:coverage xml:lang="es">Reino Unido</dc:coverage>
  <dc:subject>002B02Q: Immunomodulateurs / Immunomodulators</dc:subject>
  <dc:rights>Inist-CNRS</dc:rights>
  <dc:identifier>Inist-CNRS record number 2363647</dc:identifier>
  <dc:rights>Sauf mention contraire ci-dessus, le contenu de cette notice bibliographique peut être utilisé dans le cadre d’une licence CC BY 4.0 Inist-CNRS / Unless otherwise stated above, the content of this bibliographic record may be used under a CC BY 4.0 licence by Inist-CNRS / A menos que se haya señalado antes, el contenido de este registro bibliográfico puede ser utilizado al amparo de una licencia CC BY 4.0 Inist-CNRS</dc:rights>
</metadata>
</ListRecords>